Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shaanxi Micot Raises $16 Million for Bispecific Polypeptide Candidates

publication date: Oct 16, 2019

Shaanxi Micot Technology raised $16 million in a Pre-A financing to develop its portfolio of novel multi-targeted polypeptide drug candidates. Founded in 2007, Micot is located in Xi'an. The company says its bispecific polypeptides are activated simultaneously through separate signals to maximize bioactivity and minimize side effects. It is developing 16 candidates in cardiovascular, pain, calcium/phosphorus metabolism and diabetes indications. The round was led by Northern Light Venture Capital, with participation from Tasly Capital, Detong Capital and Shanxi Investment. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital